TOOLS AND RESOURCES
HEAR FROM EXPERTS ABOUT THE DAMAGE THAT MAY BE CAUSED BY LARGELY UNADDRESSED INFLAMMATION AND FIBROSIS IN PATIENTS WITH CKD AND T2D1-5
The Silent Nature of CKD in T2D
Increased Cardiovascular Risk in Patients with CKD and T2D
Early Detection & Intervention in CKD and T2D
The Need for a Collaborative Multidisciplinary Approach in CKD in T2D
Patient Education in CKD in T2D
The Role of Healthcare Providers Beyond the Specialists
Rajiv Agarwal, MD, takes us through how MR overactivation impacts inflammation and fibrosis and leads to CKD progression
Peter Rossing, MD, discusses the burden that CKD presents for patients with T2D
Peter Rossing, MD, helps us understand the daily management needs of those living with CKD and T2D
This video explains the mode of disease behind CKD in patients with T2D
Hear from patients around the world about their experiences living with CKD and T2D
CKD=chronic kidney disease; CV=cardiovascular; MR=mineralocorticoid receptor; T2D=type 2 diabetes; UACR=urine albumin-to-creatinine ratio.
References:
- Toth-Manikowski S, et al. J Diabetes Res. 2015;2015. doi:10:11552015/697010. Return to content
- Alicic RZ, et al. Clin J Am Soc Nephrol. 2017;12(12):2032-2045. Return to content
- Alicic RZ, et al. Adv Chronic Kidney Dis. 2018;25(2):181-191. Return to content
- Black LM, et al. J Histochem Cytochem. 2019;67(9):663-681. Return to content
- Kidney Disease: Improving Global Outcomes (KDIGO) Diabetes Work Group. Kidney Int. 2020;98(4S):S1-S115. Return to content
- Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. Kidney Int Suppl. 2013;3(1):1-150. Return to content
Follow:
© 2022 Bayer AG
Last updated in June 2022
This website is intended to provide information to an international audience of healthcare professionals outside the USA and UK.
- PP-KER-ALL-0067-1
